

Future Science Group

JOURNAL & DIGITAL PUBLISHING SOLUTIONS

JOANNE WALKER HEAD OF PUBLISHING SOLUTIONS


PRESENTED AT A MEDCOMMS NETWORKING EVENT, 5 DECEMBER 2018

WWW.MEDCOMMSNETWORKING.COM

Vision in Scientific and Medical Publishing

Agenda

- Overview of FSG
- Our Journals
- Our Publishing Solutions
- Our Digital Hubs



Future Medicine

- Clinical & translational medicine titles
- 26 journals
- 5 digital hubs

newlands press

- Titles in applied science and IP issues in R&D
- 5 journals
- 2 digital hubs



- Fully open access titles
- 2 journals
- 1 digital hub

Publishing Solutions

Our Journals

Our Journals



Journal Management

- All journals run by a Commissioning Editor and Managing Editor in collaboration with the journal's Editorial Board
- Manage pre-submission enquiries
- Commission content and ensure quality
- Pipeline management
- Editorial Board management
- Social media & marketing activities
- Journal development



Editorial Board Management

- Team of 30+ key experts from academia and industry
- Recruited at launch and refreshed on an ongoing basis
- Support the journal by:
- Providing content suggestions
- Conducting peer review of manuscript particularly difficult papers, those with a split opinion, etc.
- Providing feedback on the journal
- Writing for the journal themselves
- Acting as a journal ambassador

- Pre-submission enquiries encouraged
- Peer review by at least 3 specialists
- Editorial decision within 2 working days
- Journal cascading/transfer
- Publication standards CONSORT, COPE, GPP3 and ICMJE
- ISMPP association

Trusted, ethical publication principles



Good publication practice for communicating company

sponsored medical research: the GPP2 guidelines

Chris Graf, ¹Wendy P Battisti,² Dan Bridges,³ Victoria Bruce-Winkler,⁴ Joanne M Conaty,⁶ John M Ellison,⁶ Elizabeth A Field,⁷ James A Gurr,⁸ Mary-Ellen Marx,⁹ Mina Patel,¹⁰ Carol Sanes-Miller,⁵ Wonne E Yarker,¹¹ for the International Society for Medical Publication Professionals

In response to changes in the environment in which authors, presenters, and other contributors work together to communicate medical research the **International Society for Medical Publication Professionals** has updated the good publication practice guidelines

John Wiey & Sons, Wiey-Blackwell, Oxford 004 2DQ call ree Pohnson & Johnson their v Pharmacultical Research & indivisi Development, Rantan, NJ, USA and pr

OPE

Authors and presenters are responsible for how medical research is interpreted and communicated. Often these developments. These guidelines were written in light of these work is the product of collaborations with other individual (such as clinical invergingern, storastistican). **Method** and professional metach unrengt from control de wordt. The International Society for Medical Publication

COMMITTEE ON PUBLICATION ETHICS





Vision in Scientific and Medical Publishing | www.future-science-group.com

Pre- and post-registration studies

RWE & HEOR research

Observational studies

-

_

-

10

Future ONCOLOGY

Original Research

Research Article




- Narrative & systematic reviews
- Therapeutic overviews
- Unmet needs
- Drug, device & vaccine evaluations
- Consensus and treatment guidelines

	Future
Review	-Uture ONCOLOGY
muta	mizing outcomes in EGFR ation-positive NSCLC: which tyrosine se inhibitor and when?
¹ Thoracic On ² Thoracic Sur	Gogy Université de Lyon, Université Claude Bernard Lyon 1, Lyon, 60622, France gery, Institut Curle, Institut du Thorax Curle-Montsouris, Paris, 75248, France
*Autho Despi afatin to the follov effica	Review Immunotherapy
influe tases into t lung (Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials
	Madan Jagasia*-1, Robert Zeiser ² , Michael Arbushites ³ , Patricia Delaite ³ , Brian Gadbaw ⁴ &
	Review Talking to patients about biosimilars
	Yelena Y Janjigian*1, Marco Bissig ² , Giuseppe Curigliano ³ , Jennifer Coppola ⁴ & Mark Latymer ³ ¹ daatroimetinal Oncology Service, Memorial Soan Kettering Cancer Center & Weil Cornel Medical College, New York, NY
	1005. U/A ¹ Status de Seisens Enemoclogie Alles éviles de la Seisens Island (Statu Service Canton et et le Germanda, Lagon, Alles Note, HT ¹ Status de Seisens Enemoclogie de las Seisens Island (Statu Service Canton et el Germanda, Lagon, Alles Note, HT ¹ Status de Seisens Enemoclogie de las Seisens Island et la Oricology & Department of Hematology Oncology, University of ¹ Malano, Malan, Natus, Natus
	Biologic therapies target aberrant pathways in diseases including diabetes, cancer and autoimmune dis- orders. Despite recent scientific advances, patient access to these agents can be limited. Biosimilars are designed to be highly similar to the originator biologic, targeting the same biological pathways, with comparable efficacy and safety. Biosimilars have the advantage of lower treatment costs, offering the potential for increased clinical use and patient access. Several biosimilars are approved for clinical use in the USA and Europe, however, there is a lack of awareness about biosimilars among healthcare providers and patients. This overview of the scientific basis of biosimilars and current indications aim to enhance discussions with patients and increase understanding of the role of biosimilars in individual treatment plans.

Reviews

Clinical Trial Protocols




- Background, design and rationale of trial
- Phase 2/3 or post-registration studies

- Educate for trial recruitment
- Summary infographic


Journal Publishing Solutions

Our Publishing Options





Timely and highly engaging, well-read articles



Accelerated Publication

- Standard publication 14–18 weeks
- No page charges
- Accelerated publication 6 weeks
- \$270/page
- Online ahead of print and fully citable

Open Access – Hybrid Journals

- Open access options for all 21 subscription journals
- Fee of \$2,500
- CC BY-NC-ND license
- Copyright assigned to the author
- Options available for other OA licenses and uses



- 12 journals are currently fully OA
- Range of OA license options available
- Future Science OA -
 - CC-BY license
 - Publishes all research of relevance to human health


Open Access – Open Access Journals























Vision in Scientific and Medical Publishing | www.future-science-group.com

Social Media Reach

- All journals integrated with Twitter
- Many have sizeable LinkedIn groups
- Articles shared daily using # and @
- Attention tracked via article metrics



Tweets 1,783	Following 1,394	Followers 855	Likes 143		
Tweets Tweets & replies Media					
		ffectiveness of llagen dressing #openaccess #	f a bilayered living cellular construct and an acellular g in the treatment of venous leg ulcers #CER		
And		of adding #lesi	h sinurad for second-line treatment of #gout: a US /2HhurLQ #openaccess		
		1,0	I Population ,000,000		
		Tre 1st-line	28,569 eated with e ULT = 29% 8285		
		1 Failure	1st-line tes = 57.64% 4775		

First-, second- and third-generation EGFR TKIs: activity against EGFR m

Polishing an existing video ٠

- Creating an image-based video ٠
- Full filming and production service ٠

- videos, procedures, audio only Free
- On YouTube

-

- Added post-publication -
- Services offered in-house team -

Video abstracts, mechanism of action

TURE ONCOLOGY, AHEAD OF PRINT | REVIEW Free Access | 📀 rifluridine/tipiracil: an emerging strategy for the managemer f gastrointestinal cancers rc Peeters 🖳 Andrés Cervantes, Shanti Moreno Vera & Julien Taieb ine: 27 Apr 2018 | https://doi.org/10.2217/fon-2018-014 Tools < Share

nical value of trifluridine/tiniracil as a monoth

vords: colorectal cancer • gastrointestinal cancer • trifluridine/tipirac

care for GI cancers in the future.

nation therapy and recently completed and ongoing clinical trials. Data gathered so far

line/tipiracil has the potential to form the chemotherapeutic backbo

Videos and Video Abstracts





X X X



- Concise, visual summary of the main findings of the article
- Services offered:
- Polishing an existing images
- Full creative and design service

Graphical Abstracts


NEURODECENERATIVE DISEASE MANAGEMENT, ANEAD OF PRINT | SHORT COMMUNICATION () PREACCORD () Octagam® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies Stefan Wietekt[®]

Published Online: 8 Mar 2018 https://doi.org/10.2217/nmt-2018-0006

😑 Sections 🛓 View Article

🌶 Tools 🛛 < Share

Aim: To present data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving octagam² 5% or 10% for chronic inflarmatory demyelinating polyneuropathy (CIDP). Methods: Data on patients with OIDP treated with octagam were analyzed to assess its safety and tolerability. Results: Of 2314 patients included in the studies, 58 patients (mean age: 64.6 years) received octagam for OIDP, mean dose of which was 0.8 g/kg body weight/course. 81% of observations for clinical appearance since last observation were assessed as stable and 16.6% showed an improved clinical appearance with treatment. Adverse drug reactions were rare (<0.7% of infusions). Conclusion: Octagam was effective and well-tolerated in patients with CIDP.



Digital Publishing Solutions

Our Digital Hubs

Vision in Scientific and Medical Publishing | www.future-science-group.com

Digital Knowledge Hubs

- Complement our key journals
- Free to register online resource
- Membership based fully compliant
- Daily news and articles
- Feature selected journal articles



Vision in Scientific and Medical Publishing | www.future-science-group.com


Sharing Journal Articles on a Digital Hub

- Article abstract hosted on hub
- Link through to article exclusive for members
- Feature on the digital site homepage
- Promotion via social media
- Highlighted in the weekly newsletter

Oncology Central				
HOME DISEASE AREA 👻 TOPICS NEWS ARTICLES 🛩 OUR JOURNALS 🛩				
Sequential treatment with afatinib and osimertinib in patie Share				
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC: an observational study				
Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao et al.				
Future Oncol. (2018) doi:10.2217/fon-2018-0711				
GioTag: results of real-world study of treatment sequencing in GGFR mutation-positive lung cancer				
LUNG				
CLINICAL TRIALS				
ORIGINAL PUBLICATION DATE: 19 OCTOBER, 2018 PUBLICATION / SOURCE: FUJURE ONCOLOGY AUTHORS: MAXIMILIAN J. HOCHMAIR, ALESSANDRO MORABITO, DESIREE HAO ET AL				
Lay abstract				
GioTag is a non-interventional study based on existing medical records of patients with <i>EGFR</i> mutation-positive advanced NSCLC treated with afatinib as the first-line treatment followed by osimertinib for 1790M resistance mutation patients. In this paper find out the results of this observational real-world study and how the findings could increase our understanding of how sequencing of tyrosine kinase inhibitors can extend chemotherapy-free treatment ime.				

Medical Education Platforms

- Hubs are platforms to provide bespoke content
- Include interviews, white papers, editorials and webinars
- Video interviews present research findings and expert opinion
- Raise awareness of emerging therapies, treatment strategies and clinical trials



Our Future

- Plan S
- Video Journal
- Pharma Platforms



Contact

